Abstract
Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.
Original language | English (US) |
---|---|
Pages (from-to) | 150-158 |
Number of pages | 9 |
Journal | European Urology |
Volume | 79 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2021 |
Keywords
- Apalutamide
- Nonmetastatic castration-resistant prostate cancer
- Overall survival
- Subsequent therapy
- Time to cytotoxic chemotherapy
ASJC Scopus subject areas
- Urology